
Metabolic Health App Developer, Signos, Raises $20M in Series B Funding Including Investment from Dexcom Ventures
Signos, the California-based metabolic health platform, has successfully secured $20 million in Series B funding in a round led by Cheyenne Ventures and GV (Google Ventures). The round also saw participation from Dexcom Ventures and Samsung Next. These funds will be allocated to bolster the company’s core team and further enhance its platform focused on metabolic health.
Signos, under the leadership of CEO Sharam Fouladgar-Mercer, has pioneered a unique approach to metabolic health by combining continuous glucose information with an AI-enhanced mobile application. This innovative platform delivers crucial data and personalized recommendations aimed at promoting healthy and sustainable weight loss.The Signos app serves as an essential tool for its members, allowing them to log their dietary intake and exercise routines. The platform utilizes AI technology to analyze how an individual’s metabolism responds to different foods and fitness patterns. This comprehensive data is then used to provide tailored recommendations based on each user’s specific metabolic profile. Signos initially offered its metabolic-led solution to reverse prediabetes and aid individuals on their weight loss journeys. However, its services were exclusively available to non-diabetic populations. This year, in May 2023, Signos took a significant step forward by expanding its weight management platform to include support for individuals living with Type 2 diabetes.
Fouladgar-Mercer explained, “Sleep, stress, exercise, and diet all influence how high and sustained one’s glucose spikes can be. By providing glucose visibility, tracking, and AI-driven proactive suggestions, Signos can help users navigate those choices for better health.”